Literature DB >> 28303466

Do Statins Have Antidepressant Effects?

Ole Köhler-Forsberg1,2,3, Christiane Gasse4,5, Michael Berk6,7,8,9, Søren Dinesen Østergaard10,11.   

Abstract

Statins are used widely in primary and secondary prevention of cardiovascular disease; a treatment effect that has long been thought to be due to their cholesterol-lowering properties. However, statins also have a wide range of anti-inflammatory effects independent of their lipid-lowering mechanisms. In depression, low-grade inflammation is a replicated finding, and several studies have shown antidepressant properties of diverse anti-inflammatory drugs. Large observational studies have suggested reduced risks of depression amongst those taking statins, an effect that is thought to be explained by the anti-inflammatory properties of this class of drugs. Also, preliminary randomized controlled trials (RCTs) have indicated that statins may have adjunctive antidepressant effects when used as add-on treatment to selective serotonin reuptake inhibitors (SSRIs). However, the RCTs were small and limited by low generalizability, and some early observational studies have pointed towards potential neuropsychiatric adverse effects of statin treatment. Nevertheless, based on the good tolerability and general safety of the statins, researchers are currently investigating the potential antidepressant properties of these agents. The present review aims to give an overview on the potential antidepressant effects of statins based on their anti-inflammatory properties, covering topics such as safety versus treatment effects, potential mechanisms of action and the possibility of targeted treatment (precision medicine).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28303466     DOI: 10.1007/s40263-017-0422-3

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  96 in total

1.  Low serum cholesterol and suicide.

Authors:  H Engelberg
Journal:  Lancet       Date:  1992-03-21       Impact factor: 79.321

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

4.  Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Authors:  Chris Dickens; Linda McGowan; David Clark-Carter; Francis Creed
Journal:  Psychosom Med       Date:  2002 Jan-Feb       Impact factor: 4.312

5.  The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women.

Authors:  Adrienne O'Neil; Aaron J Fisher; Katherine J Kibbey; Felice N Jacka; Mark A Kotowicz; Lana J Williams; Amanda L Stuart; Michael Berk; Paul A Lewandowski; John J Atherton; Craig B Taylor; Julie A Pasco
Journal:  Prev Med       Date:  2016-02-22       Impact factor: 4.018

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

8.  The macrophage theory of depression.

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1991-08       Impact factor: 1.538

9.  An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

Authors:  Rudolf Uher; Katherine E Tansey; Tracy Dew; Wolfgang Maier; Ole Mors; Joanna Hauser; Mojca Zvezdana Dernovsek; Neven Henigsberg; Daniel Souery; Anne Farmer; Peter McGuffin
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

10.  Statin and Aspirin Use and the Risk of Mood Disorders among Men.

Authors:  Lana J Williams; Julie A Pasco; Mohammadreza Mohebbi; Felice N Jacka; Amanda L Stuart; Kamalesh Venugopal; Adrienne O'Neil; Michael Berk
Journal:  Int J Neuropsychopharmacol       Date:  2016-02-02       Impact factor: 5.176

View more
  8 in total

Review 1.  The concept of violent suicide, its underlying trait and neurobiology: A critical perspective.

Authors:  Birgit Ludwig; Yogesh Dwivedi
Journal:  Eur Neuropsychopharmacol       Date:  2017-12-15       Impact factor: 4.600

2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

3.  Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I.

Authors:  Graziela Vieira; Juliana Cavalli; Elaine C D Gonçalves; Tainara R Gonçalves; Larissa R Laurindo; Maíra Cola; Rafael C Dutra
Journal:  Front Pharmacol       Date:  2017-09-04       Impact factor: 5.810

4.  Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Riccardo De Giorgi; Franco De Crescenzo; Nicola Rizzo Pesci; Marieke Martens; Wendy Howard; Philip J Cowen; Catherine J Harmer
Journal:  PLoS One       Date:  2021-03-30       Impact factor: 3.240

5.  Shared genetic liability between major depressive disorder and osteoarthritis.

Authors:  Fuquan Zhang; Shuquan Rao; Ancha Baranova
Journal:  Bone Joint Res       Date:  2022-01       Impact factor: 5.853

Review 6.  Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?

Authors:  Estefania Gastaldello Moreira; Karine Maria Boll; Dalmo Guilherme Correia; Janaina Favaro Soares; Camila Rigobello; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

7.  Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies.

Authors:  Riccardo De Giorgi; Nicola Rizzo Pesci; Alice Quinton; Franco De Crescenzo; Philip J Cowen; Catherine J Harmer
Journal:  Front Psychiatry       Date:  2021-07-27       Impact factor: 4.157

Review 8.  Update on Statin Treatment in Patients with Neuropsychiatric Disorders.

Authors:  Razieh Avan; Adeleh Sahebnasagh; Javad Hashemi; Mahila Monajati; Fatemeh Faramarzi; Neil C Henney; Fabrizio Montecucco; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Life (Basel)       Date:  2021-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.